Top

Published in:

Open Access 01-01-2011 | Original Contribution

European guidelines on managing adverse effects of medication for ADHD

Authors: J. Graham, T. Banaschewski, J. Buitelaar, D. Coghill, M. Danckaerts, R. W. Dittmann, M. Döpfner, R. Hamilton, C. Hollis, M. Holtmann, M. Hulpke-Wette, M. Lecendreux, E. Rosenthal, A. Rothenberger, P. Santosh, J. Sergeant, E. Simonoff, E. Sonuga-Barke, I. C. K. Wong, A. Zuddas, H.-C. Steinhausen, E. Taylor, (for the European Guidelines Group)

Published in: European Child & Adolescent Psychiatry | Issue 1/2011

Abstract

The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical subspecialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.

http://www.ema.europa.eu/htms/human/referral/article31/methylphenidate.htm.

(1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry 56:1073–1086

(2001) Methylphenidate and narcolepsy: new indication. When modafinil fails. Prescrire Int 10:7–9

(2002) Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 58:527–536

(2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576

Aagaard L, Weber CB, Hansen EH (2010) Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007. Drug Saf 33:327–339PubMedCrossRef

Abikoff HB, Vitiello B, Riddle MA, Cunningham C, Greenhill LL, Swanson JM, Chuang SZ, Davies M, Kastelic E, Wigal SB, Evans L, Ghuman JK, Kollins SH, McCracken JT, McGough JJ, Murray DW, Posner K, Skrobala AM, Wigal T (2007) Methylphenidate effects on functional outcomes in the preschoolers with Attention-Deficit/Hyperactivity Disorder Treatment Study (PATS). J Child Adolesc Psychopharmacol 17:581–592PubMedCrossRef

Ahmann PA, Waltonen SJ, Olson KA, Theye FW, Van Erem AJ, LaPlant RJ (1993) Placebo-controlled evaluation of Ritalin side effects. Pediatrics 91:1101–1106PubMed

Allen AJ, Kurlan RM, Gilbert DL, Coffey BJ, Linder SL, Lewis DW, Winner PK, Dunn DW, Dure LS, Sallee FR, Milton DR, Mintz MI, Ricardi RK, Erenberg G, Layton LL, Feldman PD, Kelsey DK, Spencer TJ (2005) Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology 65:1941–1949PubMedCrossRef

Appleby JG (1985) Use of dextroamphetamine in epilepsy. J S C Med Assoc 81:281–282PubMed

10.

Arias AJ, Gelernter J, Chan G, Weiss RD, Brady KT, Farrer L, Kranzler HR (2008) Correlates of co-occurring ADHD in drug-dependent subjects: prevalence and features of substance dependence and psychiatric disorders. Addict Behav 33:1199–1207PubMedCrossRef

11.

Babington RG, Wedeking PW (1973) The pharmacology of seizures induced by sensitization with low intensity brain stimulation. Pharmacol Biochem Behav 1:461–467PubMedCrossRef

12.

Baker GA (2006) Depression and suicide in adolescents with epilepsy. Neurology 66:S5–S12PubMed

13.

Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E (2006) Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry 15(8):476–495PubMedCrossRef

14.

Banaschewski T, Neale BM, Rothenberger A, Roessner V (2007) Comorbidity of tic disorders and ADHD: conceptual and methodological considerations. Eur Child Adolesc Psychiatry 16(Suppl 1):5–14PubMedCrossRef

15.

Bangs ME, Tauscher-Wisniewski S, Polzer J, Zhang S, Acharya N, Desaiah D, Trzepacz PT, Allen AJ (2008) Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 47:209–218PubMedCrossRef

16.

Barkley RA, Fischer M, Smallish L, Fletcher K (2003) Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 111:97–109PubMedCrossRef

17.

Bendz LM, Scates AC (2010) Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder. Ann Pharmacother 44:185–191PubMedCrossRef

18.

Bereket A, Turan S, Karaman MG, Haklar G, Ozbay F, Yazgan MY (2005) Height, weight, IGF-I, IGFBP-3 and thyroid functions in prepubertal children with attention deficit hyperactivity disorder: effect of methylphenidate treatment. Horm Res 63:159–164PubMedCrossRef

19.

Berenson GS, Srinivasan SR, Bao W, Newman WP III, Tracy RE, Wattigney WA (1998) Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N Engl J Med 338:1650–1656PubMedCrossRef

20.

Berger S, Utech L, Fran Hazinski M (2004) Sudden death in children and adolescents. Pediatr Clin North Am 51:1653–1677PubMedCrossRef

21.

Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV (2008) Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry 165:597–603PubMedCrossRef

22.

Biederman J, Petty CR, Dolan C, Hughes S, Mick E, Monuteaux MC, Faraone SV (2008) The long-term longitudinal course of oppositional defiant disorder and conduct disorder in ADHD boys: findings from a controlled 10-year prospective longitudinal follow-up study. Psychol Med 38:1027–1036PubMed

23.

Biederman J, Petty CR, Wilens TE, Fraire MG, Purcell CA, Mick E, Monuteaux MC, Faraone SV (2008) Familial risk analyses of attention deficit hyperactivity disorder and substance use disorders. Am J Psychiatry 165:107–115PubMedCrossRef

24.

Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF (2009) Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 48:884–893PubMedCrossRef

25.

Brown TE, McMullen WJ Jr (2001) Attention deficit disorders and sleep/arousal disturbance. Ann NY Acad Sci 931:271–286PubMedCrossRef

26.

Carlson GA, Kelly KL (2003) Stimulant rebound: how common is it and what does it mean? J Child Adolesc Psychopharmacol 13:137–142PubMedCrossRef

27.

Caspi A, Langley K, Milne B, Moffitt TE, O’Donovan M, Owen MJ, Polo, Tomas M, Poulton R, Rutter M, Taylor A, Williams B, Thapar A (2008) A replicated molecular genetic basis for subtyping antisocial behavior in children with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 65:203–210PubMedCrossRef

28.

Charach A, Figueroa M, Chen S, Ickowicz A, Schachar R (2006) Stimulant treatment over 5 years: effects on growth. J Am Acad Child Adolesc Psychiatry 45:415–421PubMedCrossRef

29.

Cohen-Zion M, Ancoli-Israel S (2004) Sleep in children with attention-deficit hyperactivity disorder (ADHD): a review of naturalistic and stimulant intervention studies. Sleep Med Rev 8:379–402PubMedCrossRef

30.

Corrado D, Basso C, Thiene G (2001) Sudden cardiac death in young people with apparently normal heart. Cardiovasc Res 50:399–408PubMedCrossRef

31.

Cortese S, Faraone SV, Konofal E, Lecendreux M (2009) Sleep in children with attention-deficit/hyperactivity disorder: meta-analysis of subjective and objective studies. J Am Acad Child Adolesc Psychiatry 48:894–908PubMedCrossRef

32.

Denchev P, Kaltman JR, Schoenbaum M, Vitiello B (2010) Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. Circulation 121:1329–1337PubMedCrossRef

33.

Dunn DW, Austin JK, Perkins SM (2009) Prevalence of psychopathology in childhood epilepsy: categorical and dimensional measures. Dev Med Child Neurol 51:364–372PubMedCrossRef

34.

Eli Lilly and Co. (2006) Strattera safety information

35.

Elkins IJ, McGue M, Iacono WG (2007) Prospective effects of attention-deficit/hyperactivity disorder, conduct disorder, and sex on adolescent substance use and abuse. Arch Gen Psychiatry 64:1145–1152PubMedCrossRef

36.

Ernst M, Luckenbaugh DA, Moolchan ET, Leff MK, Allen R, Eshel N, London ED, Kimes A (2006) Behavioral predictors of substance-use initiation in adolescents with and without attention-deficit/hyperactivity disorder. Pediatrics 117:2030–2039PubMedCrossRef

37.

Faraone SV, Biederman J, Morley CP, Spencer TJ (2008) Effect of stimulants on height and weight: a review of the literature. J Am Acad Child Adolesc Psychiatry 47:994–1009PubMedCrossRef

38.

Faraone SV, Biederman J, Wilens TE, Adamson J (2007) A naturalistic study of the effects of pharmacotherapy on substance use disorders among ADHD adults. Psychol Med 37:1743–1752PubMedCrossRef

39.

Faraone SV, Giefer EE (2007) Long-term effects of methylphenidate transdermal delivery system treatment of ADHD on growth. J Am Acad Child Adolesc Psychiatry 46:1138–1147PubMedCrossRef

40.

Fayyad J, De Graaf R, Kessler R, Alonso J, Angermeyer M, Demyttenaere K, De Girolamo G, Haro JM, Karam EG, Lara C, Lepine JP, Ormel J, Posada-Villa J, Zaslavsky AM, Jin R (2007) Cross-national prevalence and correlates of adult attention-deficit hyperactivity disorder. Br J Psychiatry 190:402–409PubMedCrossRef

41.

Feijoo M, Bilbao J (1992) Seizures of sleep onset: clinical and therapeutical aspects. Clin Neuropharmacol 15:50–55PubMedCrossRef

42.

Feldman H, Crumrine P, Handen BL, Alvin R, Teodori J (1989) Methylphenidate in children with seizures and attention-deficit disorder. Am J Dis Child 143:1081–1086PubMed

43.

Feldman PD, Ruff DD, Allen AJ (2005) Atomoxetine and tics in ADHD. J Am Acad Child Adolesc Psychiatry 44:405–406PubMedCrossRef

44.

Fritz KM, Butz C (2007) Attention deficit/hyperactivity disorder and pediatric burn injury: important considerations regarding premorbid risk. Curr Opin Pediatr 19:565–569PubMedCrossRef

45.

Gadde KM, Yonish GM, Wagner HR, Foust MS, Allison DB (2006) Atomoxetine for weight reduction in obese women: a preliminary randomised controlled trial. Int J Obes (Lond) 30(7):1138–1142CrossRef

46.

Gharib H, Cook DM, Saenger PH, Bengtsson BA, Feld S, Nippoldt TB, Rodbard HW, Seibel JA, Vance ML, Zimmerman D (2003) American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children–2003 update. Endocr Pract 9:64–76PubMed

47.

Gonzalez-Heydrich J, Hsin O, Hickory M, Azeem MW, Mrakotsky C, Torres A, Mezzacappa E, DeMaso DR, Bourgeois B, Biederman J (2004) Comparisons of response to stimulant preparations in pediatric epilepsy. American Academy of Child and Adolescent Psychiatry Meeting

48.

Gould MS, Walsh BT, Munfakh JL, Kleinmann M, Duan N, Olfson M, Greenhill L, Cooper T (2009) Sudden death and use of stimulant medications in youths. Am J Psychiatry 166:992–1001PubMedCrossRef

49.

Graham J, Coghill D (2008) Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs 22:213–237PubMedCrossRef

50.

Greer CA, Alpern HP (1980) Paradoxical effects of d-amphetamine upon seizure susceptibility in 2 selectively bred lines of mice. Dev Psychobiol 13:7–15PubMedCrossRef

51.

Gross-Tsur V, Manor O, van der, Meere J, Joseph A, Shalev RS (1997) Epilepsy and attention deficit hyperactivity disorder: is methylphenidate safe and effective? J Pediatr 130:670–674PubMedCrossRef

52.

Gucuyener K, Erdemoglu AK, Senol S, Serdaroglu A, Soysal S, Kockar AI (2003) Use of methylphenidate for attention-deficit hyperactivity disorder in patients with epilepsy or electroencephalographic abnormalities. J Child Neurol 18:109–112PubMedCrossRef

53.

Halmoy A, Fasmer OB, Gillberg C, Haavik J (2009) Occupational outcome in adult ADHD: impact of symptom profile, comorbid psychiatric problems, and treatment: a cross-sectional study of 414 clinically diagnosed adult ADHD patients. J Atten Disord 13:175–187PubMedCrossRef

54.

Hanc T, Cieslik J (2008) Growth in stimulant-naive children with attention-deficit/hyperactivity disorder using cross-sectional and longitudinal approaches. Pediatrics 121:e967–e974PubMedCrossRef

55.

Hechtman L, Weiss G, Perlman T (1984) Young adult outcome of hyperactive children who received long-term stimulant treatment. J Am Acad Child Psychiatry 23:261–269PubMedCrossRef

56.

Hemmer SA, Pasternak JF, Zecker SG, Trommer BL (2001) Stimulant therapy and seizure risk in children with ADHD. Pediatr Neurol 24:99–102PubMedCrossRef

57.

Hernandez A, Barragan P (2005) Efficacy of atomoxetine treatment in children with ADHD and epilepsy. Epilepsia 46(Suppl 6):718

58.

Hesdorffer DC, Ludvigsson P, Olafsson E, Gudmundsson G, Kjartansson O, Hauser WA (2004) ADHD as a risk factor for incident unprovoked seizures and epilepsy in children. Arch Gen Psychiatry 61:731–736PubMedCrossRef

59.

Holtmann M, Becker K, Kentner-Figura B, Schmidt MH (2003) Increased frequency of rolandic spikes in ADHD children. Epilepsia 44:1241–1244PubMedCrossRef

60.

Hugtenburg JG, Griekspoor JE, De Boer I, Heerdink ER, Tso YH, Egberts AC (2005) Methylphenidate: use in daily practice. Pharm World Sci 27:197–201PubMedCrossRef

61.

Ismail D, O’Connell MA, Zacharin MR (2006) Dexamphetamine use for management of obesity and hypersomnolence following hypothalamic injury. J Pediatr Endocrinol Metab 19:129–134PubMed

62.

Jackson LV, Thalange NK, Cole TJ (2007) Blood pressure centiles for Great Britain. Arch Dis Child 92:298–303PubMedCrossRef

63.

Jasinski DR, Faries DE, Moore RJ, Schuh LM, Allen AJ (2008) Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend 95:140–146PubMedCrossRef

64.

Jerome L (2001) Can methylphenidate facilitate sleep in children with attention deficit hyperactivity disorder? J Child Adolesc Psychopharmacol 11:109PubMedCrossRef

65.

Katusic SK, Barbaresi WJ, Colligan RC, Weaver AL, Leibson CL, Jacobsen SJ (2005) Psychostimulant treatment and risk for substance abuse among young adults with a history of attention-deficit/hyperactivity disorder: a population-based, birth cohort study. J Child Adolesc Psychopharmacol 15:764–776PubMedCrossRef

66.

Keltikangas-Jarvinen L, Pulkki-Raback L, Puttonen S, Viikari J, Raitakari OT (2006) Childhood hyperactivity as a predictor of carotid artery intima media thickness over a period of 21 years: the cardiovascular risk in young Finns study. Psychosom Med 68:509–516PubMedCrossRef

67.

Kendall T, Taylor E, Perez A, Taylor C (2008) Diagnosis and management of attention-deficit/hyperactivity disorder in children, young people, and adults: summary of NICE guidance. BMJ 337:a1239PubMedCrossRef

68.

Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, Faraone SV, Greenhill LL, Howes MJ, Secnik K, Spencer T, Ustun TB, Walters EE, Zaslavsky AM (2006) The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry 163:716–723PubMedCrossRef

69.

King GA, Burnham WM (1980) Effects of d-amphetamine and apomorphine in a new animal model of petit mal epilepsy. Psychopharmacology (Berl) 69:281–285CrossRef

70.

Kinsbourne M (1973) Stimulants for insomnia. N Engl J Med 288:1129PubMed

71.

Klein RG, Landa B, Mattes JA, Klein DF (1988) Methylphenidate and growth in hyperactive children. A controlled withdrawal study. Arch Gen Psychiatry 45:1127–1130PubMed

72.

Kollins SH (2008) ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J Atten Disord 12:115–125PubMedCrossRef

73.

Kollins SH, English J, Robinson R, Hallyburton M, Chrisman AK (2008) Reinforcing and subjective effects of methylphenidate in adults with and without attention deficit hyperactivity disorder (ADHD). Psychopharmacology (Berl)

74.

Kratochvil C, Vaughan BS, Mayfield-Jorgensen ML, March J, Kollins S, Ravi H, Greenhill L, Kotler L, Paykina MA, Biggins BA, Stoner J (2006) A Pilot study of atomoxetine in young children with ADHD

75.

Krzyzaniak A, Krzywinska-Wiewiorowska M, Stawinska-Witoszynska B, Kaczmarek M, Krzych L, Kowalska M, Szilagyi-Pagowska I, Palczewska I, Karch A, Josko J, Ostrowska-Nawarycz L, Nawarycz T (2009) Blood pressure references for Polish children and adolescents. Eur J Pediatr 168:1335–1342PubMedCrossRef

76.

Laurelle MD, Abi-Dargham A, van Dyck CH (1996) Single photon emission computerised tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc Natl Acad Sci USA 93:9235–9240CrossRef

77.

Ledbetter M (2005) Atomoxetine use associated with onset of a motor tic. J Child Adolesc Psychopharmacol 15:331–333PubMedCrossRef

78.

Leddy JJ, Epstein LH, Jaroni JL, Roemmich JN, Paluch RA, Goldfield GS, Lerman C (2004) Influence of methylphenidate on eating in obese men. Obes Res 12:224–232PubMedCrossRef

79.

Lee TS, Lee TD, Lombroso PJ, King RA (2004) Atomoxetine and tics in ADHD. J Am Acad Child Adolesc Psychiatry 43:1068–1069PubMedCrossRef

80.

Leibson CL, Barbaresi WJ, Ransom J, Colligan RC, Kemner J, Weaver AL, Katusic SK (2006) Emergency department use and costs for youth with attention-deficit/hyperactivity disorder: associations with stimulant treatment. Ambul Pediatr 6:45–53PubMedCrossRef

81.

Lewington S, Clarke R, Qizilbash N, Peto R, Collins R (2002) Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903–1913PubMedCrossRef

82.

Livingston S, Pauli LL (1975) Dextroamphetamine for epilepsy. JAMA 233:278–279PubMedCrossRef

83.

Luo S, Michler K, Johnston P, Macfarlane PW (2004) A comparison of commonly used QT correction formulae: the effect of heart rate on the QTc of normal ECGs. J Electrocardiol 37(Suppl):81–90PubMedCrossRef

84.

Lurie S, O’Quinn A (1991) Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder. J Neuropsychiatry Clin Neurosci 3:41–50PubMed

85.

Mannuzza S, Klein RG, Moulton JL III (2003) Does stimulant treatment place children at risk for adult substance abuse? A controlled, prospective follow-up study. J Child Adolesc Psychopharmacol 13:273–282PubMedCrossRef

86.

Mannuzza S, Klein RG, Truong NL, Moulton JL III, Roizen ER, Howell KH, Castellanos FX (2008) Age of methylphenidate treatment initiation in children with ADHD and later substance abuse: prospective follow-up into adulthood. Am J Psychiatry 165:604–609PubMedCrossRef

87.

Markowitz JS, Patrick KS (2001) Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin Pharmacokinet 40:753–772PubMedCrossRef

88.

Marras AR, Bassareo PP, Ruscazio M (2009) The prevalence of paediatric hypertension, emphasising the need to use specific population references: the Sardinian Hypertensive Adolescents Research Programme Study. Cardiol Young 19:233–238PubMedCrossRef

89.

Martins S, Tramontina S, Polanczyk G, Eizirik M, Swanson JM, Rohde LA (2004) Weekend holidays during methylphenidate use in ADHD children: a randomized clinical trial. J Child Adolesc Psychopharmacol 14:195–206PubMedCrossRef

90.

McAfee AT, Holdridge KC, Johannes CB, Hornbuckle K, Walker AM (2008) The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database. Curr Drug Saf 3:123–131PubMedCrossRef

91.

McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC (2009) Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf 32:1089–1096PubMedCrossRef

92.

Meltzer H, Harrington R, Goodman R, Jenkins R (1999) Children and adolescents who try to harm, hurt or kill themselves. A report of further analysis from the national survey of the mental health of children and adolescents in Great Britain in 1999. HMSO, London, pp 15–49

93.

Michelson D, Read HA, Ruff DD, Witcher J, Zhang S, McCracken J (2007) CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry 46:242–251PubMedCrossRef

94.

Molina BS, Flory K, Hinshaw SP, Greiner AR, Arnold LE, Swanson JM, Hechtman L, Jensen PS, Vitiello B, Hoza B, Pelham WE, Elliott GR, Wells KC, Abikoff HB, Gibbons RD, Marcus S, Conners CK, Epstein JN, Greenhill LL, March JS, Newcorn JH, Severe JB, Wigal T (2007) Delinquent behavior and emerging substance use in the MTA at 36 months: prevalence, course, and treatment effects. J Am Acad Child Adolesc Psychiatry 46:1028–1040PubMedCrossRef

95.

Molina BS, Pelham WE (2001) Substance use, substance abuse, and LD among adolescents with a childhood history of ADHD. J Learn Disabil 34:333–342, 351

96.

Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R (2009) Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics 123:611–616PubMedCrossRef

97.

Muntner P, He J, Cutler JA, Wildman RP, Whelton PK (2004) Trends in blood pressure among children and adolescents. JAMA 291:2107–2113PubMedCrossRef

98.

Neuspiel DR, Kuller LH (1985) Sudden and unexpected natural death in childhood and adolescence. JAMA 254:1321–1325PubMedCrossRef

99.

Nissen SE (2006) ADHD drugs and cardiovascular risk. N Engl J Med 354:1445–1448PubMedCrossRef

100.

Noda T, Shimizu W, Satomi K, Suyama K, Kurita T, Aihara N, Kamakura S (2004) Classification and mechanism of Torsade de Pointes initiation in patients with congenital long QT syndrome. Eur Heart J 25:2149–2154PubMedCrossRef

101.

Odgers CL, Moffitt TE, Tach LM, Sampson A, Taylor RJ, Matthews CL, Caspi A (2009) The protective effects of neighborhood collective efficacy on British children growing up in deprivation: a developmental analysis. Dev Psychol 45:942–957PubMedCrossRef

102.

Ounsted C (1955) The hyperkinetic syndrome in epileptic children. Lancet 269:303–311PubMedCrossRef

103.

Paavonen EJ, Raikkonen K, Lahti J, Komsi N, Heinonen K, Pesonen AK, Jarvenpaa AL, Strandberg T, Kajantie E, Porkka-Heiskanen T (2009) Short sleep duration and behavioral symptoms of attention-deficit/hyperactivity disorder in healthy 7- to 8-year-old children. Pediatrics 123:e857–e864PubMedCrossRef

104.

Palumbo D, Spencer T, Lynch J, Co-Chien H, Faraone SV (2004) Emergence of tics in children with ADHD: impact of once-daily OROS methylphenidate therapy. J Child Adolesc Psychopharmacol 14:185–194PubMedCrossRef

105.

Parraga HC, Parraga KL, Harris DK, Campbell TS (2008) Abdominal tics during atomoxetine treatment in a child with ADHD: evaluation and differential diagnosis. CNS Spectr 13:E1PubMed

106.

Parraga HC, Parraga MI, Harris DK (2007) Tic exacerbation and precipitation during atomoxetine treatment in two children with attention-deficit hyperactivity disorder. Int J Psychiatry Med 37:415–424PubMedCrossRef

107.

Pesonen AK, Raikkonen K, Paavonen EJ, Heinonen K, Komsi N, Lahti J, Kajantie E, Jarvenpaa AL, Strandberg T (2009) Sleep duration and regularity are associated with behavioral problems in 8-year-old children. Int J Behav Med

108.

Pliszka SR, Matthews TL, Braslow KJ, Watson MA (2006) Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 45:520–526PubMedCrossRef

109.

Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007) The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 164:942–948PubMedCrossRef

110.

Poncin Y, Sukhodolsky DG, McGuire J, Scahill L (2007) Drug and non-drug treatments of children with ADHD and tic disorders. Eur Child Adolesc Psychiatry 16(Suppl 1):78–88PubMedCrossRef

111.

Posner K, Oquendo MA, Gould M, Stanley B, Davies M (2007) Columbia Classification Algorithm of Suicide Assessment (C-CASA): classification of suicidal events in the FDA’s pediatric suicidal risk analysis of antidepressants. Am J Psychiatry 164:1035–1043PubMedCrossRef

112.

Poulton A (2005) Growth on stimulant medication; clarifying the confusion: a review. Arch Dis Child 90:801–806PubMedCrossRef

113.

Poulton A (2006) Growth and sexual maturation in children and adolescents with attention deficit hyperactivity disorder. Curr Opin Pediatr 18:427–434PubMedCrossRef

114.

Poulton A, Cowell CT (2003) Slowing of growth in height and weight on stimulants: a characteristic pattern. J Paediatr Child Health 39:180–185PubMedCrossRef

115.

Poulton R, Caspi A, Moffitt TE, Cannon M, Murray R, Harrington H (2000) Children’s self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch Gen Psychiatry 57:1053–1058PubMedCrossRef

116.

Robertson MM (2006) Attention deficit hyperactivity disorder, tics and Tourette’s syndrome: the relationship and treatment implications. A commentary. Eur Child Adolesc Psychiatry 15:1–11PubMedCrossRef

117.

Roessner V, Becker A, Banaschewski T, Freeman RD, Rothenberger A (2007) Developmental psychopathology of children and adolescents with Tourette syndrome—impact of ADHD. Eur Child Adolesc Psychiatry 16(Suppl 1):24–35PubMedCrossRef

118.

Roessner V, Becker A, Banaschewski T, Rothenberger A (2007) Executive functions in children with chronic tic disorders with/without ADHD: new insights. Eur Child Adolesc Psychiatry 16(Suppl 1):36–44PubMedCrossRef

119.

Roessner V, Robatzek M, Knapp G, Banaschewski T, Rothenberger A (2006) First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants. Dev Med Child Neurol 48:616–621PubMedCrossRef

120.

Rothenberger A, Banaschewski T, Roessner V (2007) Tic-Störungen. Dritte Auflage, pp 319–325

121.

Rothenberger A, Roessner V, Banaschewski T, Leckman JF (2007) Co-existence of tic disorders and attention-deficit/hyperactivity disorder-recent advances in understanding and treatment. Eur Child Adolesc Psychiatry 16(Suppl 1):1–4PubMedCrossRef

122.

Sadeh A, Pergamin L, Bar-Haim Y (2006) Sleep in children with attention-deficit hyperactivity disorder: a meta-analysis of polysomnographic studies. Sleep Med Rev 10:381–398PubMedCrossRef

123.

Sangal RB, Owens J, Allen AJ, Sutton V, Schuh K, Kelsey D (2006) Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep 29:1573–1585PubMed

124.

Scahill L, Erenberg G, Berlin CM Jr, Budman C, Coffey BJ, Jankovic J, Kiessling L, King RA, Kurlan R, Lang A, Mink J, Murphy T, Zinner S, Walkup J (2006) Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 3:192–206PubMedCrossRef

125.

Schwartz G, Amor LB, Grizenko N, Lageix P, Baron C, Boivin DB, Joober R (2004) Actigraphic monitoring during sleep of children with ADHD on methylphenidate and placebo. J Am Acad Child Adolesc Psychiatry 43:1276–1282PubMedCrossRef

126.

Sears J, Patel NC (2008) Development of tics in a thirteen-year-old male following atomoxetine use. CNS Spectr 13:301–303PubMed

127.

Shillingford AJ, Glanzman MM, Ittenbach RF, Clancy RR, Gaynor JW, Wernovsky G (2008) Inattention, hyperactivity, and school performance in a population of school-age children with complex congenital heart disease. Pediatrics 121:e759–e767PubMedCrossRef

128.

Silka MJ, Hardy BG, Menashe VD, Morris CD (1998) A population-based prospective evaluation of risk of sudden cardiac death after operation for common congenital heart defects. J Am Coll Cardiol 32:245–251PubMedCrossRef

129.

Sonuga-Barke EJ, Oades RD, Psychogiou L, Chen W, Franke B, Buitelaar J, Banaschewski T, Ebstein RP, Gil M, Anney R, Miranda A, Roeyers H, Rothenberger A, Sergeant J, Steinhausen HC, Thompson M, Asherson P, Faraone SV (2009) Dopamine and serotonin transporter genotypes moderate sensitivity to maternal expressed emotion: the case of conduct and emotional problems in attention deficit/hyperactivity disorder. J Child Psychol Psychiatry 50:1052–1063PubMedCrossRef

130.

Sorof JM, Lai D, Turner J, Poffenbarger T, Portman RJ (2004) Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics 113:475–482PubMedCrossRef

131.

Spencer TJ, Biederman J, Harding M, O’Donnell D, Faraone SV, Wilens TE (1996) Growth deficits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry 35:1460–1469PubMedCrossRef

132.

Spencer TJ, Faraone SV, Biederman J, Lerner M, Cooper KM, Zimmerman B (2006) Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? J Am Acad Child Adolesc Psychiatry 45:527–537PubMedCrossRef

133.

Spencer TJ, Kratochvil CJ, Sangal RB, Saylor KE, Bailey CE, Dunn DW, Geller DA, Casat CD, Lipetz RS, Jain R, Newcorn JH, Ruff DD, Feldman PD, Furr AJ, Allen AJ (2007) Effects of atomoxetine on growth in children with attention-deficit/hyperactivity disorder following up to five years of treatment. J Child Adolesc Psychopharmacol 17:689–700PubMedCrossRef

134.

Spencer TJ, Newcorn JH, Kratochvil CJ, Ruff D, Michelson D, Biederman J (2005) Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics 116:e74–e80PubMedCrossRef

135.

Spencer TJ, Sallee FR, Gilbert DL, Dunn DW, McCracken JT, Coffey BJ, Budman CL, Ricardi RK, Leonard HL, Allen AJ, Milton DR, Feldman PD, Kelsey DK, Geller DA, Linder SL, Lewis DW, Winner PK, Kurlan RM, Mintz M (2008) Atomoxetine treatment of ADHD in children with comorbid Tourette syndrome. J Atten Disord 11:470–481PubMedCrossRef

136.

Stein D, Pat-Horenczyk R, Blank S, Dagan Y, Barak Y, Gumpel TP (2002) Sleep disturbances in adolescents with symptoms of attention-deficit/hyperactivity disorder. J Learn Disabil 35:268–275PubMedCrossRef

137.

Stein MA, Blondis TA, Schnitzler ER, O’Brien T, Fishkin J, Blackwell B, Szumowski E, Roizen NJ (1996) Methylphenidate dosing: twice daily versus three times daily. Pediatrics 98:748–756PubMed

138.

Swanson J, Greenhill L, Wigal T, Kollins S, Stehli A, Davies M, Chuang S, Vitiello B, Skrobala A, Posner K, Abikoff H, Oatis M, McCracken J, McGough J, Riddle M, Ghuman J, Cunningham C, Wigal S (2006) Stimulant-related reductions of growth rates in the PATS. J Am Acad Child Adolesc Psychiatry 45:1304–1313PubMedCrossRef

139.

Swanson JM, Elliott GR, Greenhill LL, Wigal T, Arnold LE, Vitiello B, Hechtman L, Epstein JN, Pelham WE, Abikoff HB, Newcorn JH, Molina BS, Hinshaw SP, Wells KC, Hoza B, Jensen PS, Gibbons RD, Hur K, Stehli A, Davies M, March JS, Conners CK, Caron M, Volkow ND (2007) Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. J Am Acad Child Adolesc Psychiatry 46:1015–1027PubMedCrossRef

140.

Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A (2004) European clinical guidelines for hyperkinetic disorder—first upgrade. Eur Child Adolesc Psychiatry 13(Suppl 1):17–30

141.

Thomas CR, Ayoub M, Rosenberg L, Robert RS, Meyer WJ (2004) Attention deficit hyperactivity disorder and pediatric burn injury: a preliminary retrospective study. Burns 30:221–223PubMedCrossRef

142.

Tirosh E, Sadeh A, Munvez R, Lavie P (1993) Effects of methylphenidate on sleep in children with attention-deficient hyperactivity disorder. An activity monitor study. Am J Dis Child 147:1313–1315PubMed

143.

Torres AR, Whitney J, Gonzalez-Heydrich J (2008) Attention-deficit/hyperactivity disorder in pediatric patients with epilepsy: review of pharmacological treatment. Epilepsy Behav 12:217–233PubMedCrossRef

144.

US Food and Drug Administration (2005) FDA alert: suicidal thinking in children

145.

Upadhyaya HP, Rose K, Wang W, O’Rourke K, Sullivan B, Deas D, Brady KT (2005) Attention-deficit/hyperactivity disorder, medication treatment, and substance use patterns among adolescents and young adults. J Child Adolesc Psychopharmacol 15:799–809PubMedCrossRef

146.

Vetter VL, Elia J, Erckson C, Berger S, Blum N, Uzark K, Webb CL (2008) Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young. Circulation 117:2407–2423PubMedCrossRef

147.

Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, Webb CL (2008) Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder (corrected): a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 117:2407–2423

148.

Volkow ND, Swanson JM (2003) Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 160:1909–1918PubMedCrossRef

149.

Wernicke JF, Faries D, Breitung R, Girod D (2005) QT correction methods in children and adolescents. J Cardiovasc Electrophysiol 16:76–81PubMedCrossRef

150.

Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J (2003) Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 26:729–740PubMedCrossRef

151.

Wernicke JF, Holdridge KC, Jin L, Edison T, Zhang S, Bangs ME, Allen AJ, Ball S, Dunn D (2007) Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine. Dev Med Child Neurol 49:498–502PubMedCrossRef

152.

Wilens TE, Adler LA, Adams J, Sgambati S, Rotrosen J, Sawtelle R, Utzinger L, Fusillo S (2008) Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 47:21–31PubMedCrossRef

153.

Wilens TE, Biederman J, Spencer T (1994) Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 33:424–426PubMedCrossRef

154.

Wilens TE, Faraone SV, Biederman J (2004) Attention-deficit/hyperactivity disorder in adults. JAMA 292:619–623PubMedCrossRef

155.

Wilens TE, Faraone SV, Biederman J, Gunawardene S (2003) Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111:179–185PubMedCrossRef

156.

Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J (2006) Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. J Am Acad Child Adolesc Psychiatry 45:408–414PubMedCrossRef

157.

Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A (2007) Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 120:e1494–e1501PubMedCrossRef

158.

Winterstein AG, Gerhard T, Shuster J, Saidi A (2009) Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics 124:e75–e80PubMedCrossRef

159.

Wren C (2002) Sudden death in children and adolescents. Heart 88:426–431PubMedCrossRef

160.

Yap YG, Camm AJ (2003) Drug induced QT prolongation and torsades de pointes. Heart 89:1363–1372PubMedCrossRef

161.

Young J (2008) Common comorbidities seen in adolescents with attention-deficit/hyperactivity disorder. Adolesc Med State Art Rev 19:216–228, vii

Title: European guidelines on managing adverse effects of medication for ADHD
Authors: J. Graham
T. Banaschewski
J. Buitelaar
D. Coghill
M. Danckaerts
R. W. Dittmann
M. Döpfner
R. Hamilton
C. Hollis
M. Holtmann
M. Hulpke-Wette
M. Lecendreux
E. Rosenthal
A. Rothenberger
P. Santosh
J. Sergeant
E. Simonoff
E. Sonuga-Barke
I. C. K. Wong
A. Zuddas
H.-C. Steinhausen
E. Taylor
(for the European Guidelines Group)
Publication date: 01-01-2011
Publisher: Springer-Verlag
Published in: European Child & Adolescent Psychiatry / Issue 1/2011
Print ISSN: 1018-8827
Electronic ISSN: 1435-165X
DOI: https://doi.org/10.1007/s00787-010-0140-6

At a glance: The STEP trials

Springer Medicine

European guidelines on managing adverse effects of medication for ADHD

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

Psychiatric disorders in children and adolescents presenting with unexplained chronic pain: what is the prevalence and clinical relevancy?

The risk of overlooking risks

Emotional symptoms from kindergarten to middle childhood: associations with self- and other-oriented social skills

Childhood bullying as a predictor for becoming a teenage mother in Finland